Zobrazeno 1 - 10
of 943
pro vyhledávání: '"HER2-Low"'
Autor:
Aoling Huang, Yizhi Zhao, Feng Guan, Hongfeng Zhang, Bin Luo, Ting Xie, Shuaijun Chen, Xinyue Chen, Shuying Ai, Xianli Ju, Honglin Yan, Lin Yang, Jingping Yuan
Publikováno v:
Computational and Structural Biotechnology Journal, Vol 26, Iss , Pp 40-50 (2024)
Aims: This study aimed to develop an AI algorithm for automated HER2 scoring in urothelial bladder cancer (UBCa) and assess the interobserver agreement using both manual and AI-assisted methods based on breast cancer criteria. Methods and Results: We
Externí odkaz:
https://doaj.org/article/af9ec4b1370342b5a6af974f714fbbb7
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Backgrounds To develop a machine learning (ML) model for predicting the prognosis of breast cancer (BC) patients with low human epidermal growth factor receptor 2 (HER2) expression, and to investigate the association between clinicopathologi
Externí odkaz:
https://doaj.org/article/738e5608a81a438a9eec5ec92ad8352d
Publikováno v:
Breast Cancer: Targets and Therapy, Vol Volume 16, Pp 785-793 (2024)
Hao Wang,1 Miao Yu,1 Meihua Chen,2 Hui Li,1 Shiwei Liu1 1Department of Breast, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and
Externí odkaz:
https://doaj.org/article/f03933e6f7f543778a50caaad066c360
Autor:
Yoonwon Kook, Young-jin Lee, Chihhao Chu, Ji Soo Jang, Seung Ho Baek, Soong June Bae, Yoon Jin Cha, Gyungyup Gong, Joon Jeong, Sae Byul Lee, Sung Gwe Ahn
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-10 (2024)
Abstract Background HER2-positivity is an essential marker for therapeutic decisions, while HER2 expression is heterogenous. In recent years, there has been increasing recognition of a subgroup of breast cancer patients who have low levels of HER2 ex
Externí odkaz:
https://doaj.org/article/91133285b09849d58e52027297e31a73
Autor:
Gülin Alkan Şen, Esra Aydın, Murad Guliyev, Nihan Şentürk Öztaş, Ezgi Değerli, Nebi Serkan Demirci, Zeynep Hande Turna, Fuat Hulusi Demirelli
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background The HER-2 status of breast cancer (BC) has been classified as negative or positive for a long time. Given the efficacy of novel anti-HER2-targeted antibody drug conjugates (ADCs) in HER2-low BC, a distinct subgroup of HER2-low tum
Externí odkaz:
https://doaj.org/article/98931270611d484a8f3f578cc960f2b5
Autor:
Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, Angela DeMichele, Paolo Tarantino, Evandro de Azambuja, Georg Pfeiler, Miguel Martin, Justin M. Balko, Zbigniew Nowecki, Marija Balic, Adam M. Brufsky, Arlene Chan, Patrick G. Morris, Tufia Haddad, Sibylle Loibl, Yuan Liu, Lidija Soelkner, Christian Fesl, Erica L. Mayer, Michael Gnant, on behalf of the PALLAS groups and investigators
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-10 (2024)
Abstract Background Bidirectional crosstalk between HER2 and estrogen receptor (ER) pathways may influence outcomes and the efficacy of endocrine therapy (ET). Low HER2 expression levels (HER2-low) have emerged as a predictive biomarker in patients w
Externí odkaz:
https://doaj.org/article/c4f4965043a847fba7a786c64cdbe554
Publikováno v:
Breast Cancer: Targets and Therapy, Vol Volume 16, Pp 667-678 (2024)
Man Huang,1,2,* Yudi Jin,3,* Mengyuan Wang,2 Qiang Song,4 Yanjia Fan,1 Yu Zhang,1 Cheng Tian,1 Chi Zhang,1 Shengchun Liu1 1Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, Peo
Externí odkaz:
https://doaj.org/article/8d83ddca3ce04f8994588dd14d24ddb9
Autor:
Michael Sode, Kåre Nielsen, Maj-Britt Jensen, Tobias Berg, Ann Knoop, Bent Ejlertsen, Anne-Vibeke Lænkholm
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background and purpose: We investigated the prognosis of breast cancer (BC) with low expression of human epidermal growth factor receptor 2 (HER2), as previous studies have found varying impacts on survival of HER2-low BC compared with HER2 0 BC (HER
Externí odkaz:
https://doaj.org/article/23de7ff8c85c46a18a7018b883ff9989
Autor:
Feng Guan, Xianli Ju, Lixia Chen, Jiacai Ren, Xiaokang Ke, Bin Luo, Aoling Huang, Jingping Yuan
Publikováno v:
Diagnostic Pathology, Vol 19, Iss 1, Pp 1-14 (2024)
Abstract Background This study aims to analyze potential differences in clinicopathology, efficacy of neoadjuvant therapy (NAT), and clinical outcome among HER2-null, HER2-ultralow and HER2-low breast cancers. Methods Consecutive cases of HER2-negati
Externí odkaz:
https://doaj.org/article/7c3808cd81ad4c16bdcd91245503308f
Publikováno v:
World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-15 (2024)
Abstract Background The novel anti-HER2 antibody drug conjugates (ADCs) can effectively improve the long-term survival of patients with HER2-low expression breast cancer. However, pathological responses to neoadjuvant therapy (NAT) within HER2-low ex
Externí odkaz:
https://doaj.org/article/c2b07423e5df479a9abb6a50ba6a33a5